Yahoo! Finance Search - Finance Home - Yahoo! - Help

Sunday, April 20 2014 5:03pm ET - U.S. Markets Closed.
Industry Center - Drugs - Generic
Industry Center > Drugs - Generic > News
More On This Industry
· Summary
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Drugs - Generic News
Latest News
Saturday, Apr 19, 2014
·Teva Rejected by U.S. Justice on Generic Copaxone Delay
at Bloomberg - Sat 1:36 pm ET
Friday, Apr 18, 2014
·THE MEDICINES COMPANY 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against the Medicines Company - MDCO
GlobeNewswire - Fri 10:00 pm ET
·Supreme Court Chief Justice Denies Teva's Request for an Injunction Relating to Generic Copaxone┬«; Clears Legal Hurdle for Mylan to Launch at Market Formation
PR Newswire - Fri 8:45 pm ET
·Court declines to block drug ruling in patent case
AP - Fri Apr 18
·U.S. top court denies Teva stay in Copaxone patent fight
Reuters - Fri Apr 18
·SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against The Medicines Company and Certain Officers - MDCO
Marketwire - Fri Apr 18
Thursday, Apr 17, 2014
·Impax to Sell Authorized Generic Renvela - Thu Apr 17
·[$$] Actavis, Forest Labs Get Second FTC Request for Merger Info
at The Wall Street Journal Online - Thu Apr 17
·Actavis to purchase four marketed products from Akorn and Hi-Tech Pharmacal
- Thu Apr 17
·Why Galectin Therapeutics Inc. Shares Jumped
at Motley Fool - Thu Apr 17
·Actavis to Acquire Four Products from Akorn
PR Newswire - Thu Apr 17
·Actavis and Forest Laboratories Receive FTC Second Request Under Hart-Scott-Rodino
Business Wire - Thu Apr 17
·Actavis and Forest Laboratories Receive FTC Second Request Under Hart-Scott-Rodino
PR Newswire - Thu Apr 17
·Teva willing to post bond to suspend decision on Copaxone
Reuters - Thu Apr 17
·Teva willing to post $500 million bond in Copaxone case
Reuters - Thu Apr 17
·MYL, FRX And ACT, 3 Drugs Stocks Pushing The Industry Lower
at - Thu Apr 17
·Hidden Australian Life Sciences Growth Stocks Revealed: Scott Power
at Seeking Alpha - Thu Apr 17
·Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis
GlobeNewswire - Thu Apr 17
·Akorn Completes Acquisition of Hi-Tech Pharmacal
Business Wire - Thu Apr 17
·Teva, Pfizer settle patent lawsuit over painkiller Celebrex
Reuters - Thu Apr 17
More Latest News...
Sponsor Results
The 5 Stocks To Double
Experts Favor These Stocks Today. Sign Up For This Free Report Now!
Sell Settlement for Cash
We Buy Structured Settlements. Guaranteed Best Price.
Apply for Disability
Are you eligible for up to $2642/mo in Social Security Disability?
(What's This?)

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drugs - Generic Headlines
More Finance RSS Feeds

Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2014, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?